SAR-441236 (Sanofi)

N/A

Report date: 2024/01/26 10:20:09

Base Information

Drug NameSAR-441236 (Sanofi)
Drug Alias NameTrispecific broadly neutralising antibody (Sanofi)三特异性广泛中和抗体 (赛诺菲)SAR-441236
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionHIV envelope protein gp120 CD4 binding site inhibitorsHIV envelope protein gp120 V1/V2 glycan inhibitorsTransmembrane glycoprotein gp41 membrane-proximal external region inhibitors
TargetsHIV envelope protein gp120Transmembrane glycoprotein gp41
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)SanofiThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthSanofiNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A